BioMimetic Therapeutics, Inc. to Highlight Commercial and Product Development Activities during AAOS
FRANKLIN, Tenn.--(BUSINESS WIRE)--BioMimetic Therapeutics, Inc. (NASDAQ: BMTI), a biotechnology company specializing in the development and commercialization of innovative bioactive products to promote the healing of musculoskeletal injuries and diseases, today announced its schedule of events during the American Academy of Orthopedic Surgeons (AAOS) Annual Meeting being held in San Diego, CA beginning February 16, 2011.
BioMimetic’s exhibit booth (#5541) will be located in Hall H of the San Diego Convention Center. Exhibit hours are 9:00 a.m. – 5:00 p.m. PST from February 16 – February 19. Company management will be available to answer product development questions and will host investor meetings at the exhibit booth. Please contact BioMimetic’s corporate communications department for scheduling information.
The Company will also host an analyst and investor meeting on Thursday, February 17 at 5:00 p.m. PST at the Hilton San Diego Bayfront in room 304 located on the third floor Aqua Level. The program will focus on the Company's strategy regarding the upcoming Orthopedic Advisory Panel Meeting and commercialization plans for its lead orthopedic product candidate, AugmentTM Bone Graft. Drs. Sheldon Lin and Judy Baumhauer, clinical investigators in BioMimetic’s North American pivotal trial evaluating Augment Bone Graft, will present a synopsis of the pre-clinical and clinical information expected to be presented at the upcoming panel meeting, while Company management will supply details on the U.S. commercialization plan and strategy. The meeting will also provide updates on other product candidates in the Company's pipeline, including updates on its spine program.
For guests not able to attend the analyst and investor meeting, a live audio webcast of the presentation will be available at http://phx.corporate-ir.net/phoenix.zhtml?p=irol-eventDetails&c=196896&eventID=3586713 and on the Company’s website at www.investor.biomimetics.com. Contact BioMimetic’s corporate communications department for further information.
Additionally, there will be a podium presentation during the AAOS Meeting featuring the use of rhPDGF-BB. Paper #496 entitled Effect of PDGF-Coated Suture Repair on Achilles Tendon Healing in a Rat Model will be presented by Dr. Joshua Dines, an orthopedic surgeon affiliated with the Hospital for Special Surgery Sports Medicine and Shoulder Service. The study, which demonstrated improved biomechanical properties in Achilles tendons repaired with sutures coated with rhPDGF-BB as compared to buffer-coated sutures, will be presented on Thursday, February 17 at 4:00 PST. The presentation will be held in Room 5AB Upper Level of the San Diego Convention Center.
Investor Conference Presentation
In addition to the activities being held during AAOS, Dr. Samuel Lynch, president and chief executive officer, will provide an update of corporate activities at the 2011 Canaccord Adams Musculoskeletal Conference. The presentation will take place at the Westin San Diego in the Crystal 1 Room on Tuesday, February 15 at 11:00 a.m. PST. A live audio webcast of the presentation will be available at http://www.newswire.ca/en/webcast/viewEvent.cgi?eventID=3389980 and on the Company’s website at www.biomimetics.com. The webcast will be accessible for a period of at least 30 days.
About BioMimetic Therapeutics
BioMimetic Therapeutics (NASDAQ: BMTI) is a biotechnology company specializing in the development and commercialization of innovative bioactive products to promote the healing of musculoskeletal injuries and diseases, including orthopedic, spine and sports injury applications. All products developed by BioMimetic are based upon recombinant human platelet-derived growth factor (rhPDGF-BB) platform technology, which is a synthetic form of PDGF, one of the body's principal agents to stimulate and direct healing and regeneration. Through the commercialization of this patented technology, BioMimetic seeks to become the leading company in the field of regenerative medicine by providing new treatment options for the repair of bone, cartilage, tendons and ligaments, thus helping patients recover faster from their orthopedic injuries.
In 2005, BioMimetic received marketing approval from the FDA for its first product, GEM 21S®, as a grafting material for bone and periodontal regeneration. Additionally, BioMimetic Therapeutics has completed and continues to sponsor clinical trials with its three lead product candidates Augment™ Bone Graft, Augment™ Injectable Bone Graft, and Augment™ Rotator Cuff Graft in multiple orthopedic and sports medicine indications including the treatment of foot and ankle fusions, the stimulation of healing of fractures of the wrist, and the surgical treatment of rotator cuff tears. In November 2009, BioMimetic received approval from Health Canada to begin marketing Augment Bone Graft as an alternative to the use of autograft, the current gold standard in bone grafting, in foot and ankle fusion indications in Canada. In May 2010, the Company’s Pre-Marketing Approval (PMA) application for the approval of Augment Bone Graft was filed with the FDA, and the Company anticipates approval for this product in the United States in 2011.
GEM 21S is a trademark of Luitpold Pharmaceuticals, Inc., who now owns this dental related product and markets it through its Osteohealth Company in the United States and Canada.
For further information contact Kearstin Patterson, director of corporate communications, at 615-236-4419.